Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis.

Cosimo BruniStefano GentileschiGiovanni PaciniMarco BardelliLorenzo TofaniFrancesca BartoliCaterina BaldiLaura CometiGinevra FioriFrancesca NacciClaudia FabianiSerena GuiducciAlberto Moggi-PignoneBruno FredianiMarco Matucci-Cerinic

Published in: Therapeutic advances in musculoskeletal disease (2021)

Our data on persistence of treatment and adverse events are in line with previous reports. Further large cohort studies may confirm baseline corticosteroid and NSAIDs use as predictors of SB5 interruption, helping to identify patients at higher risk of failure after switching.

Keyphrases

juvenile idiopathic arthritis
emergency department
adverse drug
electronic health record
combination therapy
deep learning